BRIEF-Cstone Pharmaceuticals Posts IFRS Loss For Year RMB2,308.4 Mln Vs Loss Of RMB1,793.1 Mln

March 26 (Reuters) - CStone Pharmaceuticals:

* IFRS LOSS FOR YEAR RMB2,308.4 MILLION VERSUS LOSS OF RMB1,793.1 MILLION

* EXPECTS TO RECEIVE NDA APPROVAL FOR TIBSOVO IN R/R AML IN TAIWAN IN 2020

* CONFIDENT IN MAXIMIZING COMMERCIAL POTENTIAL OF CO'S 5 LATE-STAGE CLINICAL DRUG CANDIDATES IN 2020 Source text for Eikon: Further company coverage: